CS5001 is the first known ROR1 antibody-drug conjugate (ADC) to demonstrate clinical anti-tumor activity in both solid tumors and lymphomas, and among the top two globally in clinical development. First-in-human study data show that CS5001 is well tolerated with promising anti-tumor activity at various dose levels in heavily pretreated, advanced solid tumors and lymphomas. Dose escalation in the.
NextCure Provides Business Update and Reports First Quarter 2024 Financial Results forextv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from forextv.com Daily Mail and Mail on Sunday newspapers.
Phase 1b data for NC410 combo with pembro to be presented at ASCO annual meeting on June 1Presented preclinical data from LNCB74 at recent AACR annual meeting Cash of approximately $96.0 million.
INCHEON, South Korea, April 24, 2024 /PRNewswire/ Samsung Biologics (KRX: 207940.KS), a global contract development and manufacturing organization (CDMO),
Poster presentation highlights strong safety and pharmacokinetic profiles for LNCB74BELTSVILLE, Md., April 08, 2024 NextCure, Inc. , a clinical-stage biopharmaceutical company committed to.